June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension and glaucoma in mice
Author Affiliations & Notes
  • Gaurang C Patel
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Yang Liu
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • J Cameron Millar
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Abbot F Clark
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Gaurang Patel, None; Yang Liu, None; J Cameron Millar, Shire Human Genetic Therapies, Inc. (F); Abbot Clark, NiCox Research Institute (F), Reata Pharmaceuticals (F), Western Commerce (C)
  • Footnotes
    Support  NEI Grant R01EY016242
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 849. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Gaurang C Patel, Yang Liu, J Cameron Millar, Abbot F Clark; Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension and glaucoma in mice. Invest. Ophthalmol. Vis. Sci. 2017;58(8):849.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glucocorticoid (GC) induced ocular hypertension (OHT) is a serious side effect of prolonged GC therapy and if left untreated it can lead to iatrogenic glaucoma and permanent vision loss. The Alternatively spliced isoform of glucocorticoid receptor GRβ acts as a dominant negative regulator of GC activity. Our previous studies have shown that GRβ regulates GC responsiveness and that overexpressing GRβ in trabecular meshwork (TM) cells inhibits GC-induced and glaucomatous damage in TM cells. The purpose of this study was to determine whether increased expression of GRβ reversed GC- induced OHT in mice.

Methods : To generate GC-OHT, C57BL/6J mice received weekly bilateral periocular (administrated through conjunctival fornix) injections of dexamethasone acetate (DEX-Ac, 200ug/eye). Several weeks after DEX-Ac administration, mouse eyes were injected intravitreally with Ad5.null or Ad5.hGRβ expression vectors (3x107 pfu/eye) to transduce TM. Intraocular pressure (IOP) was measured using TonoLab rebound tonometer, and outflow facilities were measured in living mice using our constant flow infusion technique. Fibronectin and collagen I expression were evaluated using immunoblotting from mouse anterior segment tissues. Unpaired Student’s t-test (2-tailed) and One-way ANOVA were used for statistical analysis.

Results : DEX-Ac significantly increased IOP from days 3-44 (n=23, p<0.0001), with a maximum IOP increase of 10 mmHg compared to vehicle control eyes. GRβ transduction of TM at day 19 after DEX-Ac induced OHT significantly lowered IOP (n=14, p<0.001) within 7 days to basline IOPs, thus reversing GC-OHT in mouse eyes. DEX-Ac significantly decreased the outflow facility (n=10, p<0.01) and GRβ transduction returned the outflow facility to normal levels (n=9, p<0.05). Increased expression of fibronectin and collagen I was observed in DEX-Ac treated mice compared to controls and GRβ transduced mouse eyes.

Conclusions : Overexpression of GRβ in the TM of mouse eyes reversed GC-OHT. GRβ gene therapy may be a useful therapeutic approach to treat glucocorticoid-induced ocular hypertension and glaucoma.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×